3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Breast
1
Conditions
Breast Neoplasms
7
Carcinoma, Non-Small-Cell Lung
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Meningeal Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Interventions
Radiosurgery
51
Magnetic Resonance Spectroscopy
34
Temozolomide
28
pembrolizumab
24
Bevacizumab
24
Radiotherapy
20
Nivolumab
20
Specimen Handling
14
Ipilimumab
13
Cyclophosphamide
13
Mental Status and Dementia Tests
12
Carboplatin
12
abemaciclib
10
Radiation
10
Blood Specimen Collection
9
trastuzumab deruxtecan
8
Proton Therapy
7
Pemetrexed
7
Memantine
7
fluciclovine F-18
6
binimetinib
6
Paclitaxel
6
Etoposide
6
Cisplatin
6
Capecitabine
6
encorafenib
5
Trastuzumab
5
Surveys and Questionnaires
5
Surgical Procedures, Operative
5
Lomustine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
patritumab deruxtecan
×
1 year
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled
NCT05620914
2025-06-15
PARAMETer
Duke University
Phase 2
Withdrawn